Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma,The New England Journal of Medicine

当前位置： X-MOL 学术 › N. Engl. J. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2017-09-10 , DOI: 10.1056/nejmoa1708539
Georgina V Long ₁ , Axel Hauschild ₁ , Mario Santinami ₁ , Victoria Atkinson ₁ , Mario Mandalà ₁ , Vanna Chiarion-Sileni ₁ , James Larkin ₁ , Marta Nyakas ₁ , Caroline Dutriaux ₁ , Andrew Haydon ₁ , Caroline Robert ₁ , Laurent Mortier ₁ , Jacob Schachter ₁ , Dirk Schadendorf ₁ , Thierry Lesimple ₁ , Ruth Plummer ₁ , Ran Ji ₁ , Pingkuan Zhang ₁ , Bijoyesh Mookerjee ₁ , Jeff Legos ₁ , Richard Kefford ₁ , Reinhard Dummer ₁ , John M Kirkwood ₁

Affiliation

Adjuvant use of combination therapy with dabrafenib plus trametinib resulted in a significantly lower risk of recurrence in patients with stage III melanoma with BRAF V600E or V600K mutations than the adjuvant use of placebo and was not associated with new toxic effects. (Funded by GlaxoSmithKline and Novartis; COMBI-AD ClinicalTrials.gov, NCT01682083; EudraCT number, 2012-001266-15.)

中文翻译：

达拉非尼联合 Trametinib 辅助治疗 III 期 BRAF 突变黑色素瘤

与辅助使用安慰剂相比，辅助使用达拉非尼加曲美替尼联合治疗可显着降低具有BRAF V600E 或 V600K 突变的 III 期黑色素瘤患者的复发风险，并且与新的毒性作用无关。（由葛兰素史克和诺华资助；COMBI-AD ClinicalTrials.gov， NCT01682083 ；EudraCT 编号， 2012-001266-15 。）

更新日期：2017-11-09

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文